Researchers identify a novel link between aging, metabolism and anti-cancer T-cell function
MUSC Hollings Cancer Center researchers are finding solutions to the aging-related changes that reduce anti-cancer immunity. Besim Ogretmen, Ph.D., and colleagues found a novel link between aging, metabolism and anti-cancer T-cell function. Their work, published in
Cell Reports, sheds light on an important pathway that cannot be ignored during cancer treatment.
Two broad questions in cancer research are: How can cancer treatments be improved, and what is the link between cancer and aging?
We know that the protective T-cell response deteriorates with age. Mitochondrial function is now thought to be one of the central regulators of the aging process. Our experiments connected the dots with what was previously shown and highlighted some surprising and important pathways.
MUSC Hollings Cancer Center researchers are finding solutions to the aging-related changes that reduce anti-cancer immunity. Their work, published in Cell Reports, sheds light on an important pathway that cannot be ignored during cancer treatment.
Date Time
Hollings research sheds light on connection between aging, cancer and mitochondrial function in T-cells
MUSC Hollings Cancer Center researchers are finding solutions to the aging-related changes that reduce anti-cancer immunity. Besim Ogretmen, Ph.D., and colleagues found a novel link between aging, metabolism and anti-cancer T-cell function. Their work, published in Cell Reports, sheds light on an important pathway that cannot be ignored during cancer treatment.
Two broad questions in cancer research are: How can cancer treatments be improved, and what is the link between cancer and aging?
“We know that the protective T-cell response deteriorates with age. Mitochondrial function is now thought to be one of the central regulators of the aging process. Our experiments connected the dots with what was previously shown and highlighted some surprising and important pathways,” said Ogretmen, who is the SmartState Endowed Chair in Lipidomics and Drug Discovery.
Single strain of bacteria may reduce the severity of graft-versus-host disease
MUSC Hollings Cancer Center researchers found that a single strain of bacteria may be able to reduce the severity of graft-versus-host disease (GVHD), as reported online in February 2021 in
JCI Insight.
Bone marrow transplant can be a lifesaving procedure for patients with blood cancers. However, GVHD is a potentially fatal side effect of transplantation, and it has limited treatment options. This proof-of-concept study demonstrates that better treatment options may be on the horizon for patients with GVHD.
Xue-Zhong Yu, M.D., associate director of Basic Science at Hollings Cancer Center, and lead author Hanief Sofi, Ph.D., realized that protecting the health of the gastrointestinal tract is a good target for reducing severe GVHD.